Logotype for I-Mab

I-Mab (IMAB) investor relations material

I-Mab Investor Update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for I-Mab
Investor Update summary16 Oct, 2025

Business transformation strategy

  • Transitioning to a global biotech platform, leveraging operations in both China and the US to bridge Asian innovation with global markets.

  • Adopting a hub-and-spoke model to source, develop, and out-license clinical-stage assets, focusing on maximizing value creation at proof-of-concept stages.

  • Emphasizing capabilities in clinical development, business development, and capital solutions, supported by strong partnerships and investment backing from CBC Group.

  • Systematic asset screening process, with over 550 opportunities identified and a disciplined approach to deal selection and execution.

  • Plans to expand into new therapeutic areas, starting with ophthalmology, and targeting 2–4 new molecules per year for the platform.

Pipeline and clinical updates

  • Lead asset GivaStomach (Claudin 18.2/4-1BB bispecific antibody) shows robust efficacy and favorable safety in early clinical studies for gastric cancer.

  • A randomized Phase II study for GivaStomach is planned, targeting a broad patient population, with first patient in expected in 2026.

  • Acquisition of VS-101, a bifunctional biologic for wet AMD and DME, through subsidiary Viscera, with Phase II data expected by end of year and Phase III initiation in 2026.

  • Additional pipeline assets include a PD-L1/4-1BB bispecific with promising ORR in heavily pretreated patients, and a CD73 antibody in Phase II trials for biomarker-selected populations.

Financial and operational model

  • Focus on capital efficiency by acquiring clinical-stage assets, advancing them to proof-of-concept, and monetizing through out-licensing, spin-offs, or equity/profit-sharing arrangements.

  • Typical investment per asset is around $100 million, aiming for significant value creation and potential billion-dollar exits.

  • Hub-and-spoke structure allows scientific autonomy at the asset level, with centralized support for business development and strategic partnerships.

  • Dual listing on Nasdaq and Hong Kong planned to strengthen balance sheet and access broader capital markets.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next I-Mab earnings date

Logotype for I-Mab
Q3 202513 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next I-Mab earnings date

Logotype for I-Mab
Q3 202513 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of innovative biologics, particularly in the fields of immuno-oncology and immuno-inflammation. The company has a diverse pipeline, including several antibody-based therapies aimed at treating various forms of cancer. These include drugs in different phases of clinical trials, such as Uliledlimab for solid tumors and Lemzoparlimab for hematologic malignancies. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage